147 related articles for article (PubMed ID: 37847267)
1. SGLT2 inhibitors and diabetic retinopathy progression.
Nadelmann JB; Miller CG; McGeehan B; Yu Y; VanderBeek BL
Graefes Arch Clin Exp Ophthalmol; 2024 Mar; 262(3):753-758. PubMed ID: 37847267
[TBL] [Abstract][Full Text] [Related]
2. Erythropoiesis-Stimulating Agents and the Risk of Vision-Threatening Diabetic Retinopathy.
Tsui JC; Willett K; Cohen JB; Yu Y; VanderBeek BL
Ophthalmic Epidemiol; 2024 Jun; 31(3):249-257. PubMed ID: 37427852
[TBL] [Abstract][Full Text] [Related]
3. Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy.
Meer E; Bavinger JC; Yu Y; VanderBeek BL
JAMA Ophthalmol; 2022 May; 140(5):529-532. PubMed ID: 35389455
[TBL] [Abstract][Full Text] [Related]
4. Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy.
Li Y; Yu Y; VanderBeek BL
Eye (Lond); 2020 May; 34(5):934-941. PubMed ID: 31586167
[TBL] [Abstract][Full Text] [Related]
5. Statin use and the risk of progression to vision threatening diabetic retinopathy.
Meer E; Bavinger JC; Yu Y; Hua P; McGeehan B; VanderBeek BL
Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):652-660. PubMed ID: 35253307
[TBL] [Abstract][Full Text] [Related]
6. Trends in Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Medicare Part B Fee-for-Service Beneficiaries.
Lundeen EA; Andes LJ; Rein DB; Wittenborn JS; Erdem E; Gu Q; Saaddine J; Imperatore G; Chew EY
JAMA Ophthalmol; 2022 Apr; 140(4):345-353. PubMed ID: 35238912
[TBL] [Abstract][Full Text] [Related]
7. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
Maturi RK; Glassman AR; Josic K; Antoszyk AN; Blodi BA; Jampol LM; Marcus DM; Martin DF; Melia M; Salehi-Had H; Stockdale CR; Punjabi OS; Sun JK;
JAMA Ophthalmol; 2021 Jul; 139(7):701-712. PubMed ID: 33784735
[TBL] [Abstract][Full Text] [Related]
8. Lipid-Lowering Medications Are Associated with Lower Risk of Retinopathy and Ophthalmic Interventions among United States Patients with Diabetes.
Vail D; Callaway NF; Ludwig CA; Saroj N; Moshfeghi DM
Am J Ophthalmol; 2019 Nov; 207():378-384. PubMed ID: 31194953
[TBL] [Abstract][Full Text] [Related]
9. Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice.
Moshfeghi AA; Khurana RN; Moini H; Sherman S; Reed K; Boucher N; Rahimy E
BMC Ophthalmol; 2024 May; 24(1):229. PubMed ID: 38822279
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of morphological characteristics of diabetic macular edema in patients with non-proliferative versus proliferative diabetic retinopathy: a spectral-domain optical coherence tomography study.
Chatziralli I; Theodossiadis G; Dimitriou E; Theodossiadis P
Int Ophthalmol; 2021 Jul; 41(7):2417-2424. PubMed ID: 33772414
[TBL] [Abstract][Full Text] [Related]
11. Trends in the Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Commercially Insured Adults Aged <65 Years.
Lundeen EA; Kim M; Rein DB; Wittenborn JS; Saaddine J; Ehrlich JR; Holliday CS
Diabetes Care; 2023 Apr; 46(4):687-696. PubMed ID: 36637915
[TBL] [Abstract][Full Text] [Related]
12. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK; Glassman AR; Josic K; Baker CW; Gerstenblith AT; Jampol LM; Meleth A; Martin DF; Melia M; Punjabi OS; Rofagha S; Salehi-Had H; Stockdale CR; Sun JK;
JAMA; 2023 Feb; 329(5):376-385. PubMed ID: 36749332
[TBL] [Abstract][Full Text] [Related]
13. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
14. A Cost-Effectiveness Analysis of Intravitreal Aflibercept for the Prevention of Progressive Diabetic Retinopathy.
Patel NA; Yannuzzi NA; Lin J; Smiddy WE
Ophthalmol Retina; 2022 Mar; 6(3):213-218. PubMed ID: 34547529
[TBL] [Abstract][Full Text] [Related]
15. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
[TBL] [Abstract][Full Text] [Related]
16. [Association of choroidal thickness with diabetic retinopathy at different stages].
Wang S; Lin S; Zheng Y; Di F; Cao X; Liu C; Yang J
Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(32):2584-8. PubMed ID: 26711604
[TBL] [Abstract][Full Text] [Related]
17. Association of Abnormal Renal Profiles and Proliferative Diabetic Retinopathy and Diabetic Macular Edema in an Asian Population With Type 2 Diabetes.
Hsieh YT; Tsai MJ; Tu ST; Hsieh MC
JAMA Ophthalmol; 2018 Jan; 136(1):68-74. PubMed ID: 29167896
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-like Cells Are Increased in Patients with Vision-Threatening Diabetic Retinopathy and Correlate with Macular Edema.
Zhang NT; Nesper PL; Ong JX; Wang JM; Fawzi AA; Lavine JA
Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36428853
[TBL] [Abstract][Full Text] [Related]
19. Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice.
Maloney MH; Schilz SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2019 Jul; 126(7):1007-1015. PubMed ID: 30292542
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with diabetic macular edema in patients with proliferative diabetic retinopathy.
O'Fee JR; Juliano J; Moshfeghi AA
Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2191-2200. PubMed ID: 35192029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
